Skip to main content

Biomarkers of Neuroinflammation Proceedings of a Workshop (2018) / Chapter Skim
Currently Skimming:

Appendix B Workshop Agenda
Pages 63-70

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 63...
... and blood, as well as positron emission tomography imaging agents for targets such as translocator protein. Given the intense activity in academic research and private-sector settings and across many nervous system disorders, there is an opportunity to take stock of current knowledge, provide a venue for coordination, and identify potential opportunities to advance work in this domain.
Read the entire page →
From page 64...
... Welcome and Overview of Workshop RITA BALICE-GORDON, Sanofi (Co-Chair) LINDA BRADY, National Institute of Mental Health (Co-Chair)
Read the entire page →
From page 65...
... • Discuss desirable biomarker characteristics for quantitatively tracking neuroinflammation in disease progression and therapeutic interventions in different CNS disorders.
Read the entire page →
From page 66...
... o Are current imaging agents useful in identifying specific patient populations? o What is the potential clinical utility of imaging agents and can they detect immediate and longer-term changes following therapeutic interventions?
Read the entire page →
From page 67...
... 9:55 a.m. Presentations ANNA KATRIN SZARDENINGS, Johnson & Johnson ROBERT INNIS, National Institute of Mental Health MARTINA ABSINTA, National Institute of Neurological Disorders and Stroke KATERINA AKASSOGLOU, Gladstone Institute of Neurological Disease 11:10 a.m.
Read the entire page →
From page 68...
... • Identify specific barriers and opportunities for increased coordinating among ongoing efforts in academia, the private sector, and consortia. • Brainstorm potential collaborative projects that could be submitted through the Biomarkers Consortium or other current or planned mechanisms.
Read the entire page →
From page 69...
... Panel Remarks EDWARD BULLMORE, University of Cambridge and GlaxoSmithKline GARY LANDRETH, Case Western Reserve University RICHARD PERRIN, Washington University in St. Louis AMIT BAR-OR, University of Pennsylvania ANNA KATRIN SZARDENINGS, Johnson & Johnson ANDREW MILLER, Emory University TAREK SAMAD, Pfizer Inc.
Read the entire page →

Key Terms

  • fluid biomarkers
  • cns disorders
  • imaging biomarkers
  • current knowledge
  • imaging agents

  • share methodological
  • clinical utility
  • identifying specific
  • session overview
  • clinical development

  • current imaging
  • potential clinical
  • methodological approaches
  • identify biomarkers
  • regulatory decision

  • discuss approaches
  • linda brady
  • potential collaborative
  • richard perrin
  • regulatory issues

  • recent findings
  • biomarkers useful
  • compelling genetic
  • current consortia
  • neuroimaging methods

  • validate imaging
  • desirable biomarker
  • collaborative projects
  • gary landreth
  • highlight approaches


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.